Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 171,303,072
  • Shares Outstanding, K 2,735,160
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.81
  • Price/Sales 4.32
  • Price/Cash Flow 10.86
  • Price/Book 4.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.24 +0.63%
on 07/11/17
66.40 -5.68%
on 06/26/17
-2.83 (-4.32%)
since 06/21/17
3-Month
62.02 +0.98%
on 04/24/17
66.40 -5.68%
on 06/26/17
+0.74 (+1.20%)
since 04/21/17
52-Week
57.18 +9.53%
on 08/03/16
66.80 -6.24%
on 03/01/17
+3.84 (+6.53%)
since 07/21/16

Most Recent Stories

More News
Merck's Biosimilar Insulin Gets Tentative FDA Approval

Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

MRK : 62.63 (-0.49%)
LLY : 84.66 (-0.11%)
PFE : 33.48 (-0.18%)
SNY : 47.71 (-0.73%)
What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?

Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.

MRK : 62.63 (-0.49%)
VRTX : 163.17 (+2.41%)
GILD : 73.76 (+0.46%)
BMY : 55.65 (+0.38%)
Can Merck (MRK) Pull Off a Surprise this Earnings Season?

Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition....

NVO : 42.95 (-1.38%)
MRK : 62.63 (-0.49%)
VRTX : 163.17 (+2.41%)
PFE : 33.48 (-0.18%)
Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

AZN : 34.05 (+0.47%)
JNJ : 135.31 (-0.92%)
MRK : 62.63 (-0.49%)
LLY : 84.66 (-0.11%)
NVS : 84.99 (-0.50%)
SNY : 47.71 (-0.73%)
BMY : 55.65 (+0.38%)
European Medicines Agency's CHMP Recommends Approval for Merck's KEYTRUDA(R) (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer

--Positive Opinion is Based on Overall Survival Benefit Demonstrated in the Phase 3 KEYNOTE-045 Trial and Durable Responses Observed in the Phase 2 KEYNOTE-052 Trial

MRK : 62.63 (-0.49%)
Asian shares meander as ECB, BOJ hold monetary policy steady

TOKYO (AP) — Asian shares were mixed Friday in muted trading after the European Central Bank announced no changes to its stimulus policies.

ABT : 50.84 (-0.02%)
SHW : 352.17 (+0.40%)
MRK : 62.63 (-0.49%)
JNJ : 135.31 (-0.92%)
SHLD : 8.83 (-8.02%)
HD : 146.65 (-0.26%)
PM : 119.58 (-0.23%)
AMZN : 1,025.67 (-0.29%)
Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Packaging

GLW : 31.85 (+0.44%)
MRK : 62.63 (-0.49%)
PFE : 33.48 (-0.18%)
Merck Announces U.S. FDA Grants Tentative Approval for LUSDUNA(TM) Nexvue(TM) (insulin glargine injection), a Follow-On Biologic Basal Insulin

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for LUSDUNA(TM) Nexvue(TM)...

MRK : 62.63 (-0.49%)
Watch for Shares of Merck & Co (MRK) to Approach Resistance at $62.80

Merck & Co (NYSE:MRK) has opened bullishly above the pivot of $62.44 today and has reached the first level of resistance at $62.60. Investors may be interested in a cross of the next upside pivot targets...

MRK : 62.63 (-0.49%)
Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck's KEYTRUDA in Non-Small Cell Lung Cancer

Biothera Pharmaceuticals, Inc. today announced that the Big Ten Cancer Research Consortium has begun patient dosing in a Phase 1b/2 clinical study to evaluate Biothera's Imprime PGG in combination with...

MRK : 62.63 (-0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 63.16
1st Resistance Point 62.89
Last Price 62.63
1st Support Level 62.47
2nd Support Level 62.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.